Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates into potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, cardiac contractility, and acid-base balance. Replacement of potassium corrects hypokalemia.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Treatment and prevention of hypokalemia,Digitalis intoxication,Correction of hypokalemia in patients with metabolic acidosis,Maintenance of potassium levels during diuretic therapy
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
20-40 m Eq potassium chloride intravenously per dose, infused at a rate not exceeding 10 m Eq/hour (or 20 m Eq/hour in critical care settings), repeated as needed based on serum potassium levels. Maximum daily dose typically 200 m Eq.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Potassium chloride does not have a classic elimination half-life as it is an endogenous electrolyte. The terminal half-life of exogenous potassium is approximately 2-3 hours in healthy individuals, reflecting rapid cellular uptake and renal clearance. In renal impairment, half-life is prolonged.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is not metabolized; it is primarily excreted renally (90%) via passive glomerular filtration and active secretion in the distal tubules. Minor losses occur via feces and sweat.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Renal excretion is the primary route; >90% of potassium is excreted by the kidneys, with a small amount lost in feces (via gastrointestinal secretion) and negligible biliary excretion. Renal elimination is regulated by aldosterone and tubular secretion.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Potassium is not significantly protein-bound; <1% is bound to plasma proteins. It exists primarily as free ions in plasma.
70–80% (primarily to albumin).
Approximately 0.5-0.6 L/kg in adults, reflecting distribution into total body water. Potassium is predominantly intracellular; the apparent Vd is low due to rapid cellular uptake. Clinical meaning: a large Vd would indicate poor cellular uptake or loss from cells.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Oral potassium chloride has a bioavailability of approximately 90-100% as it is well absorbed from the gastrointestinal tract. Intravenous potassium chloride has 100% bioavailability.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
GFR 30-59 m L/min: Administer with caution, reduce dose by 25-50% and monitor potassium closely. GFR <30 m L/min: Contraindicated or use only if severely deficient with extreme caution; reduce dose by at least 50% and avoid sustained release formulations. Hemodialysis: Use only with close monitoring; typical dose 10-20 m Eq per session.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 25% and monitor potassium. Child-Pugh C: Avoid use unless potassium severely deficient; reduce dose by at least 50% with frequent monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Intravenous dose: 0.5-1 m Eq/kg/dose, infused at a rate not exceeding 0.5-1 m Eq/kg/hour, maximum single dose 20 m Eq. For mild hypokalemia: 0.5-1 m Eq/kg/day divided. For severe: up to 2 m Eq/kg/day with monitoring. Not to exceed 1 m Eq/kg/hour or 20 m Eq/hour.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Start at lower end of adult dosing (10-20 m Eq) due to increased risk of hyperkalemia and renal impairment. Maximum infusion rate 10 m Eq/hour. Use with caution and monitor potassium levels frequently; avoid potassium-sparing diuretics and ACE inhibitors.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Potassium chloride injection concentrate must be diluted before use. Rapid infusion or high concentrations may cause fatal hyperkalemia, cardiac arrest, or arrhythmias. Intravenous administration must be via a large-bore vein with continuous cardiac monitoring.
No FDA black box warning is present for HEMICLOR.
Risk of hyperkalemia in renal impairment,Avoid in severe renal failure with oliguria,Monitor serum potassium and ECG during IV administration,Use with caution in patients with cardiac disease, adrenal insufficiency, or metabolic acidosis,Extravasation may cause tissue necrosis
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia,Severe renal failure with oliguria/anuria,Addison's disease,Acute dehydration,Heat cramps,Concurrent potassium-sparing diuretics,Patients on spironolactone, eplerenone, or amiloride
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, legumes, salt substitutes containing potassium) while on potassium therapy to prevent hyperkalemia. Consult dietitian for balanced intake.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
No evidence of teratogenicity in first trimester. Physiological potassium homeostasis is critical; severe maternal hypokalemia may increase risk of fetal adverse effects. No dose-limiting fetal toxicity reported.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium is a normal constituent of breast milk. Intravenous potassium chloride administration does not significantly alter milk potassium concentration. M/P ratio not established but expected to be <1. Considered compatible with breastfeeding.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
Pregnancy induces increased plasma volume and renal potassium excretion. Lower baseline potassium levels may require higher doses to maintain normokalemia. Titrate based on frequent serum potassium monitoring; no fixed dose adjustment.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Potassium chloride 10 m Eq in plastic container (typically 100 m L volume) is used for correction of hypokalemia. Administer via peripheral or central line; for peripheral infusion, rates should not exceed 10 m Eq/hour and concentration should not exceed 40 m Eq/L to avoid phlebitis. In critical care, may use higher concentrations via central line with cardiac monitoring. Always assess renal function before administration; do not give in severe renal impairment or hyperkalemia. Potassium is irritating to veins; ensure proper IV site rotation.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Report any burning or pain at the IV site immediately.,Do not stop or adjust the infusion rate; the nurse will manage it.,Inform your doctor if you have kidney problems or are taking medications that increase potassium (e.g., ACE inhibitors, spironolactone).,Symptoms of too much potassium include muscle weakness, irregular heartbeat, or numbness/tingling.,This medication is replacing potassium lost from your body; it is important to follow dietary potassium guidance.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER vs HEMICLOR, answered by our medical review team.
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates into potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, cardiac contractility, and acid-base balance. Replacement of potassium corrects hypokalemia.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER and HEMICLOR depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER is: 20-40 m Eq potassium chloride intravenously per dose, infused at a rate not exceeding 10 m Eq/hour (or 20 m Eq/hour in critical care settings), repeated as needed based on serum potassium levels. Maximum daily dose typically 200 m Eq.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in first trimester. Physiological potassium homeostasis is critical; severe maternal hypokalemia may increase risk of fetal adverse effects. No dose-l. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.